Key result
A cartilage-derived inhibitor of angiogenesis may control deregulated vascular growth characteristic of angiogenic diseases by inhibiting metalloproteinase activity.
Why the study?
Does a cartilage-derived metalloproteinase inhibitor prevent neovascularization in in vivo and in vitro models?
Population
In vivo and in vitro models of angiogenesis (capillary endothelial cells)
Design
Preclinical
Authors
Loading...
May support metalloproteinase inhibition for angiogenic diseases; leaves open clinical translation from animal models.
Does a cartilage-derived metalloproteinase inhibitor prevent neovascularization in in vivo and in vitro models?
Inhibition of metalloproteinases by a cartilage-derived inhibitor may serve as a therapeutic strategy for controlling deregulated angiogenesis.
Moses et al. (1991) conducted a review in Angiogenic diseases. Cartilage-derived inhibitor (CDI) of angiogenesis was evaluated on Neovascularization / angiogenesis. A cartilage-derived inhibitor of angiogenesis may control deregulated vascular growth characteristic of angiogenic diseases by inhibiting metalloproteinase activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: